28 November 2024

CPHI India
PMEC India

Daily News

Published by : PHARMACLICK

DAY 3

News AT A GLANCE



CPHI and PMEC India helping pharma industry...

Page No. 16



AI, IoT, block-chain shaping pharma...

Page No. 20

Bioaltus Pharma-ceuticals poised for...

Page No. 24



How to Commer-cialize an Ad-vanced...

Page No. 42

Advertiser Index - Pg 60

Sustainability takes centre stage on second day of CPHI India expo

LAXMI YADAV, MUMBAI

PHARMACEUTICAL stalwarts have underscored the necessity of a multifaceted approach to address significant sustainability issues facing the Indian pharmaceutical and biopharma industries, including energy efficiency, waste reduction, lifecycle assessments, eco-friendly packaging, supplier collaboration and transition to net-zero.

Speaking at a leadership panel discussion on "Addressing the Critical Sustainability Challenges in Indian Pharma & Biopharma" on second day of CPHI India expo in Noida on November 27, the industry captains also highlighted the need for charting the right roadmap towards sustainability with Environmental, Social, and Governance (ESG) goals.

Moderated by Chakravarthi AVPS, Global Ambassador, World Packaging Organisation, the panel discussion featured Jerome Gnanaprakasam, Vice President, Dr. Reddy's Laboratories; Sunila Sahasrabudhe, Head -ESG Finance, Biocon; Himanshu Gupta-Director Sales - South Asia, Veolia Water Technologies & Solutions; Chandi Prasad Ravipati, Head Packaging Development, Aurobindo Pharma.

CONTINUED ON p8▶

Global harmonization for patient access to generic drugs involves aligning regulatory standards and processes across countries to streamline the approval, production, and distribution of affordable medications. This approach ensures consistent quality, safety, and efficacy of generic drugs while reducing duplication of clinical trials and regulatory reviews. Harmonization fosters collaboration between international regulatory bodies, minimizes barriers to trade, and accelerates market entry for generics, ultimately benefiting patients by enhancing accessibility to cost-effective treatments. By addressing disparities in regulatory frameworks, global harmonization strengthens healthcare systems, supports innovation, and promotes equitable access to essential medicines worldwide.

Here are some insights from industry experts on it.

Global harmonization for patient access to generic drugs

"GLOBAL harmonization in the pharmaceutical industry is essential for improving patient access to generic drugs. As demand for affordable medications increases, especially in low- and middle-income countries, harmonizing regulatory standards for generics becomes a priority. Generic drugs, which are cost-effective alternatives to brand-name medications, play a pivotal role in making healthcare more accessible. However, regulatory discrepancies across countries can delay market entry, limiting patient access to these life-saving medicines.

Efforts to harmonize regulatory frameworks, such as those led by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), aim to streamline the approval process. This ensures that generics meet the same standards of safety, efficacy, and quality as their branded counterparts. By aligning guidelines, countries can reduce time and costs associated with approval procedures, ultimately making generics available to a broader population more quickly.

Global harmonization also fosters innovation by encouraging competition, driving prices down, and increasing affordability. As a result, patients worldwide benefit from improved access to essential medications, and healthcare systems are better equipped to manage public health challenges. Achieving this harmonization requires cooperation between regulatory bodies, industry stakeholders, and governments, but the long-term benefits are undeniable.

Dr Sanjay Agrawal, Scientific Advisor, Alkomex Pharma Inc, USA